Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natesto for Hypogonadism and Spermatogenesis Maintenance
NCT04717362Phase 1Withdrawn
- Sponsor
- Baylor College of Medicine
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of natesto in Hypogonadism, infertility and testosterone deficiency (TD), sponsored by Baylor College of Medicine. Primary endpoint: Change in Semen Analysis at 26 weeks. Planned start Mar 2024; status: withdrawn.
02
Drugs
natesto
03
Conditions
Hypogonadisminfertilitytestosterone deficiency (TD)
Beyond the preview
Go deeper on NCT04717362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04717362.